4basebio UK Societas (4BB) AI Stock Analysis

• Market Cap: £89.04M
• Dividend Yield: N/A
• Average Volume (3M): 999.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.40
• Revenue Growth: 198.49%
• EPS Growth: -26.66%
• Country: UK
• Employees: 101
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 15,538,518
• 10 Day Avg. Volume: 230
• 30 Day Avg. Volume: 999
• PEG Ratio: -0.25
• Price to Book (P/B): 6.02
• Price to Sales (P/S): 170.11
• P/FCF Ratio: -12.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: 549.00p ▼(-10.73% Downside)

The overall stock score is primarily impacted by the company's challenging financial performance and bearish technical indicators. The negative valuation metrics further weigh down the score. While the CEO's share purchase is a positive sign, it does not significantly offset the financial and technical weaknesses.

Positive Factors

Stable demand for GMP-grade pDNA

4basebio’s core business supplies GMP-grade plasmid DNA to gene therapy, cell therapy and vaccine developers. This addresses a structural, growing need for high-quality DNA starting materials with regulatory and technical barriers, supporting durable contract demand and long-term revenue runway.

Strong recent revenue growth

Near-200% revenue growth indicates meaningful commercial traction and expanding customer adoption of its manufacturing and services. Sustained top-line expansion can validate the business model, enable scale efficiencies and justify continued investment in capacity and process improvements over the medium term.

Improving equity position

A move from negative to positive equity strengthens the balance sheet, reducing insolvency risk and improving ability to fund capex or process scale-up. This structural improvement enhances long-term financial flexibility and credibility with partners and customers for multi-year contracts.

Negative Factors

Persistent operating losses

Ongoing negative margins show the business currently fails to convert revenue into sustainable profits. Over months this necessitates either sustained capital raises or material margin improvement via pricing, yield gains or cost control to avoid diluting shareholders or constraining reinvestment.

Negative operating and free cash flow

Operating and free cash flow deficits mean the company cannot self-fund growth or working capital, increasing reliance on external financing. This structural cash generation weakness elevates refinancing risk and can limit timely investment in capacity, delaying commercialization progress.

Moderate leverage on the balance sheet

A moderate debt burden reduces financial flexibility and increases fixed obligations. Combined with losses and negative cash flow, leverage raises the risk that adverse operational swings or slower revenue realization will pressure liquidity and force costly refinancing or operational cuts.

4basebio UK Societas Business Overview & Revenue Model

Company Description

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.

How the Company Makes Money

4basebio generates revenue through multiple streams, primarily by developing and licensing its proprietary gene editing technologies to pharmaceutical and biotechnology companies. The company engages in collaborative research partnerships, which often include milestone payments and royalties on future sales of developed therapies. Additionally, 4BB may earn revenue from clinical trial services and consulting engagements with clients seeking expertise in synthetic biology. Significant partnerships with leading research institutions and biopharmaceutical firms enhance its revenue potential and broaden its market reach.

4basebio UK Societas Financial Statement Overview

Summary

4basebio UK Societas is facing financial challenges with continuous losses and cash flow struggles. Despite revenue growth and an improved equity position, the company needs to enhance operational efficiency and profitability.

Income Statement

4basebio UK Societas has shown some revenue growth, with a notable increase from 2023 to 2024. However, the company faces persistent losses, with a negative net profit margin and EBIT margin indicating ongoing profitability challenges. The gross profit margin is relatively healthy but overshadowed by high operating losses.

Balance Sheet

The company maintains a strong equity position with a positive equity ratio. However, the debt-to-equity ratio indicates a moderate level of leverage, which can be a risk for financial stability. The consistent increase in stockholders' equity from negative in 2023 to positive in 2024 is a positive sign of improving financial structure.

Cash Flow

The cash flow situation is concerning, with negative operating and free cash flows. Although there was a significant increase in financing cash flow in 2024, it primarily reflects external funding rather than strong operational performance. The negative free cash flow to net income ratio indicates inefficiency in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.78M	933.00K	506.00K	268.00K	338.00K	462.00K
Gross Profit	100.00K	630.00K	340.00K	239.00K	269.00K	274.00K
EBITDA	-15.18M	-10.97M	-7.34M	-5.41M	-3.21M	-346.00K
Net Income	-14.41M	-12.33M	-7.67M	-5.15M	-3.23M	-719.00K
Balance Sheet
Total Assets	36.87M	44.73M	11.92M	11.69M	14.70M	17.81M
Cash, Cash Equivalents and Short-Term Investments	26.11M	34.60M	3.07M	4.35M	9.59M	15.00M
Total Debt	15.44M	15.22M	10.46M	3.35M	1.76M	1.72M
Total Liabilities	17.89M	18.35M	12.41M	4.57M	3.01M	2.35M
Stockholders Equity	18.98M	26.38M	-492.00K	7.12M	11.70M	15.46M
Cash Flow
Free Cash Flow	-14.04M	-12.31M	-7.67M	-6.64M	-4.25M	-1.87M
Operating Cash Flow	-13.21M	-10.74M	-6.18M	-4.70M	-2.74M	-1.02M
Investing Cash Flow	-1.52M	-1.57M	-1.49M	-1.94M	-1.51M	1.45M
Financing Cash Flow	38.06M	43.87M	6.42M	1.24M	-467.00K	14.43M

4basebio UK Societas Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 615.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:4BB, the sentiment is Negative. The current price of 615 is above the 20-day moving average (MA) of 589.75, below the 50-day MA of 643.95, and below the 200-day MA of 861.94, indicating a bearish trend. The MACD of -19.86 indicates Negative momentum. The RSI at 5.78 is Positive, neither overbought nor oversold. The STOCH value of 31.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:4BB.

4basebio UK Societas Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£96.66M	13.08	64.40%	8.33%	-3.61%	-6.35%
APTA	52 Neutral	£23.60M	-6.25	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FAB	44 Neutral	£16.88M	-9.38	-164.37%	―	-11.43%	23.40%
AVCT	42 Neutral	£225.26M	―	―	―	―	―
4BB	41 Neutral	£89.04M	-5.79	-209.34%	―	198.49%	-26.66%
OBD	38 Underperform	£11.80M	-0.29	-407.49%	―	72.17%	79.03%